Search research articles
Contact Us
Filters
Showing results (291-300 of 395) with videos related to
Page
of 40
Sort By:
Arthritis and Rheumatism
|
December 1, 2007
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom
Allison L Smitten, Hyon K Choi, Marc C Hochberg, et al.
Journal of Chemotherapy (Florence, Italy)
|
June 1, 1993
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma
V Gebbia, A Testa, R Valenza, et al.
Anticancer Research
|
May 1, 1994
Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma
V Gebbia, M Caruso, R Valenza, et al.
International Journal of Clinical Practice
|
April 23, 2014
Endocarditis caused by Streptococcus infantarius subsp. infantarius: a report of two cases
J Corredoira Sánchez, F García-Garrote, M J García-País, et al.
European Review for Medical and Pharmacological Sciences
|
August 17, 2006
Prevalence of HCV antibodies in autoimmune thyroid disease
A Testa, P Castaldi, V Fant, et al.
Oncology
|
November 1, 1993
A phase II study of levofolinic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma
V Gebbia, A Testa, R Valenza, et al.
Anticancer Research
|
January 12, 2000
Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study
V Gebbia, N Borsellino, A Testa, et al.
American Journal of Clinical Oncology
|
June 11, 1999
Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM)
G Colucci, F Giuliani, V Gebbia, et al.
The New England Journal of Medicine
|
April 27, 1995
Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?
S E Andrade, A M Walker, L K Gottlieb, et al.
Minerva Cardioangiologica
|
March 25, 2005
How to use the C-reactive protein in cardiac disease?
S Ursella, M Mazzone, G Portale, et al.
Page
of 40
Search research articles
Search
Showing results (291-300 of 395) with videos related to
Sort By:
Page
of 40
Arthritis and Rheumatism
|
December 1, 2007
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom
Allison L Smitten, Hyon K Choi, Marc C Hochberg, et al.
Journal of Chemotherapy (Florence, Italy)
|
June 1, 1993
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma
V Gebbia, A Testa, R Valenza, et al.
Anticancer Research
|
May 1, 1994
Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma
V Gebbia, M Caruso, R Valenza, et al.
International Journal of Clinical Practice
|
April 23, 2014
Endocarditis caused by Streptococcus infantarius subsp. infantarius: a report of two cases
J Corredoira Sánchez, F García-Garrote, M J García-País, et al.
European Review for Medical and Pharmacological Sciences
|
August 17, 2006
Prevalence of HCV antibodies in autoimmune thyroid disease
A Testa, P Castaldi, V Fant, et al.
Oncology
|
November 1, 1993
A phase II study of levofolinic acid and 5-fluorouracil plus cisplatin in patients with advanced head and neck squamous cell carcinoma
V Gebbia, A Testa, R Valenza, et al.
Anticancer Research
|
January 12, 2000
Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study
V Gebbia, N Borsellino, A Testa, et al.
American Journal of Clinical Oncology
|
June 11, 1999
Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM)
G Colucci, F Giuliani, V Gebbia, et al.
The New England Journal of Medicine
|
April 27, 1995
Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?
S E Andrade, A M Walker, L K Gottlieb, et al.
Minerva Cardioangiologica
|
March 25, 2005
How to use the C-reactive protein in cardiac disease?
S Ursella, M Mazzone, G Portale, et al.
Page
of 40